Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 14 | 2025 | 523 | 2.070 |
Why?
|
| Brain Neoplasms | 17 | 2025 | 1350 | 1.700 |
Why?
|
| Brain Stem Neoplasms | 7 | 2023 | 42 | 1.580 |
Why?
|
| Medulloblastoma | 8 | 2021 | 390 | 0.720 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2024 | 214 | 0.710 |
Why?
|
| Antineoplastic Agents | 7 | 2023 | 1796 | 0.660 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2025 | 614 | 0.640 |
Why?
|
| Chemoradiotherapy | 6 | 2025 | 125 | 0.600 |
Why?
|
| Xenograft Model Antitumor Assays | 10 | 2023 | 999 | 0.580 |
Why?
|
| Polycomb Repressive Complex 1 | 2 | 2014 | 28 | 0.540 |
Why?
|
| Cerebellar Neoplasms | 5 | 2021 | 328 | 0.510 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2025 | 1312 | 0.470 |
Why?
|
| Antigens, CD | 2 | 2014 | 410 | 0.440 |
Why?
|
| Ependymoma | 3 | 2025 | 154 | 0.440 |
Why?
|
| Glycoproteins | 2 | 2014 | 346 | 0.440 |
Why?
|
| Peptides | 2 | 2014 | 708 | 0.400 |
Why?
|
| Pyrimidines | 3 | 2023 | 452 | 0.400 |
Why?
|
| Optic Nerve Glioma | 2 | 2025 | 21 | 0.390 |
Why?
|
| Glioblastoma | 3 | 2023 | 378 | 0.380 |
Why?
|
| Down-Regulation | 1 | 2014 | 655 | 0.380 |
Why?
|
| Benzimidazoles | 4 | 2025 | 155 | 0.370 |
Why?
|
| Oncolytic Viruses | 3 | 2023 | 86 | 0.350 |
Why?
|
| Proton Therapy | 2 | 2025 | 159 | 0.350 |
Why?
|
| Child | 32 | 2025 | 26160 | 0.340 |
Why?
|
| AC133 Antigen | 3 | 2024 | 36 | 0.340 |
Why?
|
| Oncolytic Virotherapy | 3 | 2023 | 107 | 0.340 |
Why?
|
| Neoplastic Stem Cells | 4 | 2024 | 334 | 0.330 |
Why?
|
| Mice, SCID | 12 | 2023 | 589 | 0.320 |
Why?
|
| Wilms Tumor | 2 | 2019 | 117 | 0.300 |
Why?
|
| von Willebrand Diseases | 1 | 2009 | 55 | 0.280 |
Why?
|
| Neuroimaging | 2 | 2020 | 389 | 0.250 |
Why?
|
| Neoplasm Grading | 6 | 2025 | 277 | 0.250 |
Why?
|
| Disease Models, Animal | 9 | 2023 | 4664 | 0.240 |
Why?
|
| Child, Preschool | 16 | 2025 | 14984 | 0.230 |
Why?
|
| Neoplasm Invasiveness | 2 | 2024 | 628 | 0.220 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2025 | 68 | 0.220 |
Why?
|
| Piperazines | 2 | 2021 | 270 | 0.220 |
Why?
|
| Visual Acuity | 2 | 2025 | 529 | 0.220 |
Why?
|
| CD57 Antigens | 1 | 2024 | 5 | 0.220 |
Why?
|
| Astrocytoma | 1 | 2025 | 107 | 0.210 |
Why?
|
| Humans | 42 | 2025 | 130372 | 0.210 |
Why?
|
| Fireflies | 1 | 2023 | 1 | 0.210 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2023 | 20 | 0.200 |
Why?
|
| Gangliosides | 1 | 2024 | 71 | 0.200 |
Why?
|
| Sexual Harassment | 1 | 2023 | 19 | 0.190 |
Why?
|
| Cell Line, Tumor | 9 | 2023 | 3720 | 0.190 |
Why?
|
| Rhabdoid Tumor | 1 | 2023 | 49 | 0.190 |
Why?
|
| Mice | 14 | 2024 | 18213 | 0.180 |
Why?
|
| Animals | 20 | 2024 | 33924 | 0.180 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2019 | 850 | 0.180 |
Why?
|
| Neutropenia | 1 | 2023 | 203 | 0.180 |
Why?
|
| Aurora Kinase A | 2 | 2023 | 36 | 0.180 |
Why?
|
| Azepines | 2 | 2023 | 62 | 0.180 |
Why?
|
| Symporters | 1 | 2022 | 78 | 0.180 |
Why?
|
| Biomarkers, Tumor | 4 | 2021 | 1606 | 0.180 |
Why?
|
| Thrombocytopenia | 1 | 2023 | 220 | 0.180 |
Why?
|
| Adolescent | 16 | 2025 | 20747 | 0.180 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2021 | 70 | 0.170 |
Why?
|
| Neoplasm Transplantation | 3 | 2020 | 360 | 0.170 |
Why?
|
| Craniospinal Irradiation | 1 | 2021 | 60 | 0.170 |
Why?
|
| Gadolinium | 1 | 2021 | 110 | 0.160 |
Why?
|
| Mice, Inbred NOD | 4 | 2023 | 301 | 0.160 |
Why?
|
| Thalidomide | 1 | 2020 | 39 | 0.160 |
Why?
|
| Transplantation, Heterologous | 4 | 2014 | 257 | 0.160 |
Why?
|
| Male | 24 | 2025 | 64517 | 0.160 |
Why?
|
| Endpoint Determination | 1 | 2020 | 56 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 2026 | 0.160 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2020 | 112 | 0.150 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 277 | 0.150 |
Why?
|
| Follow-Up Studies | 6 | 2025 | 5185 | 0.150 |
Why?
|
| Prognosis | 6 | 2025 | 4893 | 0.150 |
Why?
|
| Pyridines | 1 | 2021 | 259 | 0.150 |
Why?
|
| Neurofibromin 1 | 1 | 2019 | 59 | 0.150 |
Why?
|
| Receptors, Cell Surface | 1 | 2021 | 420 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 568 | 0.140 |
Why?
|
| Female | 23 | 2025 | 70274 | 0.140 |
Why?
|
| Digoxin | 1 | 2018 | 37 | 0.140 |
Why?
|
| Drug Repositioning | 1 | 2018 | 31 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 1275 | 0.140 |
Why?
|
| Systems Biology | 1 | 2018 | 60 | 0.140 |
Why?
|
| Capecitabine | 1 | 2017 | 20 | 0.140 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 146 | 0.140 |
Why?
|
| Survival Analysis | 5 | 2020 | 1498 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2025 | 3814 | 0.130 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 1829 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2020 | 381 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 265 | 0.130 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2025 | 219 | 0.130 |
Why?
|
| Germinoma | 1 | 2016 | 29 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 62 | 0.120 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2017 | 233 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 726 | 0.110 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2014 | 19 | 0.110 |
Why?
|
| Disease Progression | 4 | 2025 | 2207 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 1091 | 0.110 |
Why?
|
| Eukaryotic Initiation Factor-4G | 1 | 2014 | 46 | 0.110 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2014 | 23 | 0.110 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2014 | 39 | 0.110 |
Why?
|
| Blood-Brain Barrier | 2 | 2018 | 154 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2021 | 896 | 0.110 |
Why?
|
| Young Adult | 7 | 2024 | 9989 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 161 | 0.100 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2014 | 44 | 0.100 |
Why?
|
| Supratentorial Neoplasms | 1 | 2014 | 41 | 0.100 |
Why?
|
| Picornaviridae | 1 | 2013 | 19 | 0.100 |
Why?
|
| Mice, Nude | 1 | 2014 | 701 | 0.100 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2014 | 126 | 0.100 |
Why?
|
| Cell Adhesion | 1 | 2014 | 307 | 0.100 |
Why?
|
| Administration, Oral | 2 | 2017 | 695 | 0.100 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 667 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 361 | 0.090 |
Why?
|
| Radiotherapy Dosage | 2 | 2021 | 221 | 0.080 |
Why?
|
| Thiourea | 1 | 2010 | 10 | 0.080 |
Why?
|
| Infant | 5 | 2024 | 13269 | 0.080 |
Why?
|
| Survival Rate | 3 | 2025 | 2131 | 0.080 |
Why?
|
| Half-Life | 1 | 2010 | 150 | 0.080 |
Why?
|
| Area Under Curve | 1 | 2010 | 319 | 0.080 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 236 | 0.070 |
Why?
|
| Macaca mulatta | 1 | 2010 | 495 | 0.070 |
Why?
|
| Apoptosis | 4 | 2018 | 1843 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 1229 | 0.070 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 288 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1232 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2025 | 17606 | 0.060 |
Why?
|
| Recurrence | 2 | 2022 | 1481 | 0.060 |
Why?
|
| Kinetics | 1 | 2009 | 1087 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2021 | 2478 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 985 | 0.060 |
Why?
|
| Models, Biological | 1 | 2010 | 1390 | 0.060 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 23 | 0.050 |
Why?
|
| Cell Movement | 2 | 2021 | 871 | 0.050 |
Why?
|
| Pons | 1 | 2023 | 34 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 1608 | 0.050 |
Why?
|
| Mutation | 3 | 2023 | 6131 | 0.050 |
Why?
|
| Attitude | 1 | 2023 | 108 | 0.050 |
Why?
|
| Canada | 1 | 2023 | 321 | 0.040 |
Why?
|
| Injections, Intravenous | 2 | 2013 | 238 | 0.040 |
Why?
|
| Morpholines | 1 | 2021 | 67 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 148 | 0.040 |
Why?
|
| Dissection | 1 | 2021 | 57 | 0.040 |
Why?
|
| Biphenyl Compounds | 1 | 2021 | 75 | 0.040 |
Why?
|
| Benzamides | 1 | 2021 | 125 | 0.040 |
Why?
|
| Brain | 3 | 2021 | 3192 | 0.040 |
Why?
|
| Protons | 1 | 2021 | 98 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 2106 | 0.040 |
Why?
|
| Dactinomycin | 1 | 2020 | 47 | 0.040 |
Why?
|
| Everolimus | 1 | 2021 | 48 | 0.040 |
Why?
|
| Serial Passage | 1 | 2020 | 19 | 0.040 |
Why?
|
| Patient-Specific Modeling | 1 | 2020 | 12 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 49 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 65 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2021 | 63 | 0.040 |
Why?
|
| Pyridones | 1 | 2021 | 147 | 0.040 |
Why?
|
| Purines | 1 | 2021 | 115 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2020 | 81 | 0.040 |
Why?
|
| Perfusion Imaging | 1 | 2020 | 12 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2025 | 810 | 0.040 |
Why?
|
| Cisplatin | 1 | 2021 | 271 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 1237 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2020 | 60 | 0.040 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 116 | 0.040 |
Why?
|
| Mercaptopurine | 1 | 2019 | 72 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2021 | 174 | 0.040 |
Why?
|
| Valproic Acid | 1 | 2020 | 136 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2020 | 240 | 0.040 |
Why?
|
| Vision Disorders | 1 | 2021 | 196 | 0.040 |
Why?
|
| Allopurinol | 1 | 2019 | 79 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2019 | 60 | 0.040 |
Why?
|
| Adult | 4 | 2021 | 31117 | 0.040 |
Why?
|
| Radiation, Ionizing | 1 | 2018 | 38 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 1215 | 0.040 |
Why?
|
| Age of Onset | 1 | 2020 | 598 | 0.040 |
Why?
|
| Neurofibromatosis 1 | 1 | 2019 | 71 | 0.040 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 236 | 0.040 |
Why?
|
| Sarcoma, Ewing | 1 | 2019 | 120 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2021 | 288 | 0.030 |
Why?
|
| Tablets | 1 | 2017 | 37 | 0.030 |
Why?
|
| Contrast Media | 1 | 2021 | 491 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 767 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2018 | 330 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 1300 | 0.030 |
Why?
|
| Disease Management | 1 | 2021 | 559 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1617 | 0.030 |
Why?
|
| Craniotomy | 1 | 2017 | 108 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 950 | 0.030 |
Why?
|
| Osteosarcoma | 1 | 2019 | 275 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2020 | 2847 | 0.030 |
Why?
|
| Rhabdomyosarcoma | 1 | 2019 | 228 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2022 | 1092 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2018 | 767 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2012 | 2567 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 193 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1125 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2021 | 12855 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 2297 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 2835 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2019 | 544 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2014 | 142 | 0.030 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2013 | 23 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 706 | 0.020 |
Why?
|
| Algorithms | 1 | 2020 | 1679 | 0.020 |
Why?
|
| Mitochondria | 1 | 2018 | 764 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 225 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 4001 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2014 | 809 | 0.020 |
Why?
|
| Primary Cell Culture | 1 | 2012 | 106 | 0.020 |
Why?
|
| Genomics | 1 | 2019 | 1619 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 236 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2014 | 1018 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1723 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 6186 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 528 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 1004 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 1019 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 3393 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2905 | 0.020 |
Why?
|
| Cryopreservation | 1 | 2008 | 77 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2008 | 286 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 6421 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 4675 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 4701 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 1976 | 0.010 |
Why?
|